Dürr H K, Maroske D, Zelder O, Bode J C
Gut. 1978 Mar;19(3):175-9. doi: 10.1136/gut.19.3.175.
The results of a double-blind trial of glucagon in 69 patients with acute pancreatitis are reported. In a subgroup of 59 patients statistical analysis showed no significant differences between the glucagon-treated (n = 29; 2 X 5 mg protamine-zinc glucagon intramuscularly per day) and the placebo-treated (n = 30) subjects for the following data: duration of pain left spontaneously and induced by palpation, amounts of analgesics and antispasmodics required by the patients, duration of hospital stay, amylase activities in serum and 24 hour urine collections. Mortality rates did not differ significantly between the glucagon-treated and the placebo-treated subjects in the total group of 69 patients and in the two subgroups of patients who were treated conservatively (n = 59) and those who underwent laparotomy because of severe peritonitis (n = 10). From the results of this study it is concluded that favourable effects of glucagon upon the course of acute pancreatitis--if they do exist--are not significant.
报告了对69例急性胰腺炎患者进行胰高血糖素双盲试验的结果。在59例患者的亚组中，统计分析显示，对于以下数据，接受胰高血糖素治疗的患者（n = 29；每天肌肉注射2次5 mg精蛋白锌胰高血糖素）和接受安慰剂治疗的患者（n = 30）之间无显著差异：疼痛自发缓解及触诊诱发疼痛的持续时间、患者所需止痛剂和解痉剂的用量、住院时间、血清和24小时尿液收集的淀粉酶活性。在69例患者的总组中，以及在保守治疗的患者亚组（n = 59）和因严重腹膜炎接受剖腹手术的患者亚组（n = 10）中，接受胰高血糖素治疗的患者和接受安慰剂治疗的患者的死亡率无显著差异。从本研究结果得出结论，胰高血糖素对急性胰腺炎病程的有利影响——如果确实存在——并不显著。
